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of expertise have organized, collaborative links with 
community home care services and sufﬁcient resources.
CONCLUSIONS: Home chemotherapy requires a well-
integrated multidisciplinary team of health professionals
in partnership with selected patients and their informal
caregivers. Our study shows the need for regionalized
approaches within centralized standard setting and
funding, increased resources and support for program
evaluation, and a comprehensive cancer care model.
DIABETES—Economic Outcomes
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OBJECTIVES: Poor glycaemic control is associated with
increased risk of micro- and macro-vascular disease in
type 2 diabetes (T2D) patients. Switching patients from
metformin to Glucovance (combined glibenclamide/
metformin) leads to improved glycaemic control in pre-
viously poorly controlled patients. No long-term studies
have been performed that compare complication rates,
mortality, and long-term costs in patients switched from
metformin to Glucovance. A method was sought to link
the effects on glycaemic control of switching from met-
formin to Glucovance to long-term complication rates
and associated costs. METHODS: A validated model was
used to quantify the improvements in life expectancy
(LE), the changes in total lifetime costs (TC) associated
with the improved glycaemic control seen with switching
patients from metformin to Glucovance. Standard
Markov modelling was used to describe the long-term
incidence and progression of diabetes-related complica-
tions (angina, MI, stroke, heart failure, peripheral vascu-
lar disease, neuropathy, foot ulcer, amputation, renal
disease, and eye disease). Probabilities of complications
and HbA1c-dependent adjustments were derived from
published studies. Switching from metformin to Glucov-
ance lead to a 1% point improvement in HbA1c. Direct
costs of diabetes complications and treatment with either
metformin or Glucovance were projected over patients’
lifetimes (discounted 5% p.a.). Costs of complications
were retrieved from published sources. A French third
party payer perspective was taken. A typical type 2 
diabetes cohort (baseline age of 59) was simulated over a
30 years period. Exstensive sensitivity analysis was 
performed. RESULTS: Improved glycaemic control 
after switching from metformin to Glucovance lead to
decreased incidence and progression of diabetes-related
complications, with an increase in LE of 0.80 years, and
reduction in TC/patient of €2,050. CONCLUSIONS:
Switching from metformin to Glucovance is dominant to
maintaining patients on MET monotherapy with poor
control. Further long-term clinical studies with economic
data collection are required to conﬁrm these results.
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OBJECTIVES: To estimate the cost-effectiveness of
glycemic control with pioglitazone hydrochloride com-
pared to conventional treatment for Japanese patients
with Type II diabetes. METHODS: This study used the
Japanese Diabetes Risk Simulation Software to estimate
the lifetime cost per life-year or quality-adjusted life year
(QALY). The hypothetical cohort was comprised of 1000
individuals living in Japan, aged 50 years, who were
newly diagnosed as having Type II diabetes without
retinopathy, nephropathy complications or history of
coronary heart disease (CHD). Clinical effectiveness data
were taken from the results of clinical trials conducted in
Japan. Cost data were based on the fee schedule used for
hospital outpatients in 2000. Costs (in 2000, Japanese
yen), life expectancy and QALYs were discounted at 3%
per annum. RESULTS: Glycemic control with pioglita-
zone hydrochloride reduced the cumulative incidence of
blindness, dialysis and CHD by 22.2%, 12.2% and
7.9%, respectively. As a result, it produced a net saving
of 390,000 yen per patient over the lifetime despite the
additional annual cost of 70,000 yen for pharmacother-
apy. Increased life expectancy was 0.61 years, and 0.68
QALYs was gained. CONCLUSIONS: Glycemic control
with pioglitazone hydrochloride reduces costs and
improves health outcomes relative to conventional treat-
ment in patients with Type II diabetes in Japanese clini-
cal settings.
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OBJECTIVES: In the Diabetes Prevention Program
(DPP), overweight patients with impaired glucose toler-
ance randomized to either intensive lifestyle changes
(ILC) or metformin (MET) reduced their risk of develop-
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ing type 2 diabetes (T2D) by 58% and 31% respectively,
vs. controls. A model was developed to explore the long-
term cost-effectiveness of DPP interventions in France,
Germany, and UK. METHODS: A Markov model simu-
lated 3 states: “IGT”, “T2D”, and “dead”. Probabilities
were derived from DPP and published mortality data. 
Life expectancy (LE) was calculated for each treat-
ment arm. Country-speciﬁc direct costs were retrieved
from published sources. Lifetime costs/patient (TC) were 
calculated. Incremental cost-effectiveness ratios were 
calculated (costs/life-year gained [C/LYG]). (TC and LE
discounted 5% p.a.). Extensive sensitivity analysis was
performed to identify parameters with important impacts
on outcomes. RESULTS: Time to onset of diabetes was
8.27, 14.44, and 10.76 years for placebo, ILC, or met-
formin respectively. Delaying the onset of T2D with either
ILC or MET improved discounted LE vs. placebo by 0.19
and 0.08 years respectively. ILC lead to TC increases vs.
placebo of €2958, 1365, and 1707/patient for France,
Germany and UK respectively; and for MET increases vs.
placebo of €636, 374, and 316/patient for France,
Germany and UK respectively. C/LYG were: France—ILC
vs. placebo €15,568 and MET vs. placebo €7,950;
Germany—ILC vs. placebo €7,184 and MET vs. placebo
€4,675; and UK—ILC vs. placebo €8,984 and MET vs.
placebo €3,950. Results were most sensitive to the prob-
abilities of developing T2D, the relative risk of mortality
for the state T2D compared to IGT, and the costs of
implementing the DPP. CONCLUSIONS: ILC and MET
delayed diabetes onset and lead to improvements in LE.
Both ILC and MET were highly cost-effective in all 3
countries (i.e. C/LYG < €28,000).
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OBJECTIVES: The Irbesartan in Diabetic Nephropathy
Trial (IDNT) demonstrated a 20% and 23% reduction
compared to no treatment or amlodipine respectively in
the combined endpoint of doubling of serum creatinine
(DSC), end-stage renal disease (ESRD) or death in
patients with hypertension (treated with all antihyperten-
sive drugs except ACE-inhibitors and Ca-antagonists),
type 2 diabetes and overt nephropathy (H-T2DM-N). A
simulation model was developed to project the long-term
cost-consequences of the IDNT in Belgium and France.
METHODS: A Markov model simulated progression
from nephropathy to DSC, ESRD, death, and cardiovas-
cular events in H-T2DM-N treated with irbesartan,
amlodipine, or placebo. Treatment-speciﬁc probabilities
were derived from IDNT. Country-speciﬁc ESRD-related
transition probabilities were retrieved to reﬂect local
management practices and ESRD outcomes. Country-
speciﬁc costs were derived from published sources. A 25-
year time horizon was used. Mean total lifetime costs
(TC) and life expectancy (LE) were calculated for patients
with baseline age 59 years (mean age of the IDNT pop-
ulation). Future costs and beneﬁts were discounted at 3%
p.a. Sensitivity analysis was performed to identify 
parameters with an important impact, and to assess the
effect of varying key assumptions on the robustness of 
the model. RESULTS: In Belgium, irbesartan lead to
improved LE of 0.62 years and 0.42 years, and projected
25 year TC savings of €11,776 and €20,132/patient
versus no treatment or amlodipine respectively. In France,
improvements in LE were similar, but cost savings were
greater (TC savings of €14,382 and €23,249 versus
placebo or amlodipine respectively). The results were
robust under a wide range of plausible assumptions.
CONCLUSIONS: Treating hypertensive type 2 diabetes
patients with nephropathy using irbesartan was both
cost- and life-saving compared to amlodipine or antihy-
pertensive therapy alone.
DIABETES—Clinical Outcomes
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OBJECTIVE: Comparing a ﬁxed combination of an
ACE-inhibitor and a Non-Dihydropyridine-Calcium-
Channel-Blocker (trandolapril/verapamil) with other
medications in the treatment of hypertensive type-2 dia-
betics to determine medical consequences of a beneﬁcial
metabolic effect as judged by HbA1c value. METHODS:
A computer model was developed in order to assess long-
term effects of various levels of HbA1c on diabetes-
related complications for hypertensive patients with
diabetes type-2, who were treated with ﬁxed antihyper-
tensive combinations. Data from 2 clinical studies were
extrapolated to 10 years. The expected event rate was 
calculated per treatment group, based on UKPDS data.
Complications included in the model: renal failure, pho-
tocoagulation, vitreous hemorrhage, blindness, cataract
extraction, amputation, myocardial infarction, angina,
